Discloses 2-substituted-4- (5- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl) pentanamidobucanoic acid. The present invention also relates to a method for the treatment of osteoporosis, acute myelogenous leukemia, sickle cell disease, focal segmental glomerulosclerosis, fibrosis, aortic valvular stenosis associated with Williams syndrome, αVβ3 expressing tumor, tumor metastasis, bone resorption, T-cell lymphoma, Retinopathy, age-related macular degeneration, diabetic retinitis, and herpes simplex virus infections. The above can also be used to inhibit tumor angiogenesis.
展开▼
